Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD)
September 2006
Glaxo will be promoting Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD).
It's the first drug approved for this use.
Up to 10% of people at northern latitudes get depressed in the fall and winter. It's thought that shorter days trigger changes in melatonin, serotonin, and other neurotransmitters.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote